Uulke A Van Der Heide

List of Publications by Year
in descending order

164	8,297	43973	53109
papers	citations	48 h-index	85 g-index

168	168	168	6221
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	MRI/linac integration. Radiotherapy and Oncology, 2008, 86, 25-29.	0.3	444
2	The EMBRACE II study: The outcome and prospect of two decades of evolution within the GEC-ESTRO GYN working group and the EMBRACE studies. Clinical and Translational Radiation Oncology, 2018, 9, 48-60.	0.9	415
3	Automatic segmentation of the prostate in 3D MR images by atlas matching using localized mutual information. Medical Physics, 2008, 35, 1407-1417.	1.6	356
4	Intrafraction Motion of the Prostate During External-Beam Radiation Therapy: Analysis of 427 Patients with Implanted Fiducial Markers. International Journal of Radiation Oncology Biology Physics, 2007, 69, 419-425.	0.4	343
5	Focal Boost to the Intraprostatic Tumor in External Beam Radiotherapy for Patients With Localized Prostate Cancer: Results From the FLAME Randomized Phase III Trial. Journal of Clinical Oncology, 2021, 39, 787-796.	0.8	267
6	Label Fusion in Atlas-Based Segmentation Using a Selective and Iterative Method for Performance Level Estimation (SIMPLE). IEEE Transactions on Medical Imaging, 2010, 29, 2000-2008.	5.4	233
7	Recommendations for implementing stereotactic radiotherapy in peripheral stage IA non-small cell lung cancer: report from the Quality Assurance Working Party of the randomised phase III ROSEL study. Radiation Oncology, 2009, 4, 1.	1.2	226
8	Simultaneous MRI diffusion and perfusion imaging for tumor delineation in prostate cancer patients. Radiotherapy and Oncology, 2010, 95, 185-190.	0.3	219
9	Effect of Translational and Rotational Errors on Complex Dose Distributions With Off-Line and On-Line Position Verification. International Journal of Radiation Oncology Biology Physics, 2009, 74, 1600-1608.	0.4	193
10	Conventional, conformal, and intensity-modulated radiation therapy treatment planning of external beam radiotherapy for cervical cancer: The impact of tumor regression. International Journal of Radiation Oncology Biology Physics, 2006, 64, 189-196.	0.4	182
11	Clinical feasibility study for the use of implanted gold seeds in the prostate as reliable positioning markers during megavoltage irradiation. Radiotherapy and Oncology, 2003, 67, 295-302.	0.3	162
12	Single blind randomized Phase III trial to investigate the benefit of a focal lesion ablative microboost in prostate cancer (FLAME-trial): study protocol for a randomized controlled trial. Trials, 2011, 12, 255.	0.7	156
13	Measurements and clinical consequences of prostate motion during a radiotherapy fraction. International Journal of Radiation Oncology Biology Physics, 2002, 53, 206-214.	0.4	147
14	Motion and deformation of the target volumes during IMRT for cervical cancer: What margins do we need?. Radiotherapy and Oncology, 2008, 88, 233-240.	0.3	141
15	Analysis of fiducial marker-based position verification in the external beam radiotherapy of patients with prostate cancer. Radiotherapy and Oncology, 2007, 82, 38-45.	0.3	137
16	Functional MRI for radiotherapy dose painting. Magnetic Resonance Imaging, 2012, 30, 1216-1223.	1.0	136
17	The transformation of radiation oncology using real-time magnetic resonance guidance: A review. European Journal of Cancer, 2019, 122, 42-52.	1.3	136
18	Magnetic Resonance Imaging-Guided Adaptive Radiation Therapy: A â€œGame Changerâ€•for Prostate Treatment?. International Journal of Radiation Oncology Biology Physics, 2018, 100, 361-373.	0.4	132

#	Article	IF	Citations
19	Boosting imaging defined dominant prostatic tumors: A systematic review. Radiotherapy and Oncology, 2013, 107, 274-281.	0.3	115
20	Comparison of megavoltage position verification for prostate irradiation based on bony anatomy and implanted fiducials. Radiotherapy and Oncology, 2003, 68, 81-88.	0.3	111
21	MRI commissioning of 1.5T MR-linac systems â€“ a multi-institutional study. Radiotherapy and Oncology, 2019, 132, 114-120.	0.3	111
22	Primary endpoint analysis of the multicentre phase II hypo-FLAME trial for intermediate and high risk prostate cancer. Radiotherapy and Oncology, 2020, 147, 92-98.	0.3	109
23	Prostate tumor delineation using multiparametric magnetic resonance imaging: Inter-observer variability and pathology validation. Radiotherapy and Oncology, 2015, 115, 186-190.	0.3	102
24	Acute Toxicity After Image-Guided Intensity Modulated Radiation Therapy Compared to 3D Conformal Radiation Therapy in Prostate Cancer Patients. International Journal of Radiation Oncology Biology Physics, 2015, 91, 737-744.	0.4	102
25	Standard whole prostate gland radiotherapy with and without lesion boost in prostate cancer: Toxicity in the FLAME randomized controlled trial. Radiotherapy and Oncology, 2018, 127, 74-80.	0.3	101
26	Validation of functional imaging with pathology for tumor delineation in the prostate. Radiotherapy and Oncology, 2010, 94, 145-150.	0.3	97
27	Simultaneous multi-modality ROI delineation in clinical practice. Computer Methods and Programs in Biomedicine, 2009, 96, 133-140.	2.6	91
28	Registration of Cervical MRI Using Multifeature Mutual Information. IEEE Transactions on Medical Imaging, 2009, 28, 1412-1421.	5.4	84
29	The MOMENTUM Study: An International Registry for the Evidence-Based Introduction of MR-Guided Adaptive Therapy. Frontiers in Oncology, 2020, 10, 1328.	1.3	81
30	Feasibility and accuracy of quantitative imaging on a 1.5 T MR-linear accelerator. Radiotherapy and Oncology, 2019, 133, 156-162.	0.3	80
31	High-dose intensity-modulated radiotherapy for prostate cancer using daily fiducial marker-based position verification: acute and late toxicity in 331 patients. Radiation Oncology, 2008, 3, 15.	1.2	79
32	Late Side Effects After Image Guided Intensity Modulated Radiation Therapy Compared to 3D-Conformal Radiation Therapy for Prostate Cancer: Results From 2 Prospective Cohorts. International Journal of Radiation Oncology Biology Physics, 2016, 95, 680-689.	0.4	79
33	Quantitative imaging for radiotherapy purposes. Radiotherapy and Oncology, 2020, 146, 66-75.	0.3	71
34	Long-term experience with transrectal and transperineal implantations of fiducial gold markers in the prostate for position verification in external beam radiotherapy; feasibility, toxicity and quality of life. Radiotherapy and Oncology, 2010, 96, 38-42.	0.3	70
35	Orientation Changes of the Myosin Light Chain Domain During Filament Sliding in Active and Rigor Muscle. Journal of Molecular Biology, 2002, 318, 1275-1291.	2.0	69
36	Pathologic Validation of a Model Based on Diffusion-Weighted Imaging and Dynamic Contrast-Enhanced Magnetic Resonance Imaging for Tumor Delineation in the Prostate Peripheral Zone. International Journal of Radiation Oncology Biology Physics, 2012, 82, e537-e544.	0.4	68

#	Article	IF	Citations
37	Health-Related Quality of Life in Patients With Locally Advanced Prostate Cancer After 76 Gy Intensity-Modulated Radiotherapy vs. 70 Gy Conformal Radiotherapy in a Prospective andÂLongitudinalÂStudy. International Journal of Radiation Oncology Biology Physics, 2007, 69, 656-661.	0.4	66
38	Consensus opinion on MRI simulation for external beam radiation treatment planning. Radiotherapy and Oncology, 2016, 121, 187-192.	0.3	66
39	Online MRI guidance for healthy tissue sparing in patients with cervical cancer: An IMRT planning study. Radiotherapy and Oncology, 2008, 88, 241-249.	0.3	65
40	Quality Assurance of 4D-CT Scan Techniques in Multicenter Phase III Trial of Surgery Versus Stereotactic Radiotherapy (Radiosurgery or Surgery for Operable Early Stage (Stage 1A)) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 622 Td (N Physics, 2011, 80, 918-927.	0.4	64
41	ESTRO ACROP consensus guideline on the use of image guided radiation therapy for localized prostate cancer. Radiotherapy and Oncology, 2019, 141, 5-13.	0.3	62
42	ADC measurements on the Unity MR-linac â€“ A recommendation on behalf of the Elekta Unity MR-linac consortium. Radiotherapy and Oncology, 2020, 153, 106-113.	0.3	60
43	Technologyâ€driven research for radiotherapy innovation. Molecular Oncology, 2020, 14, 1500-1513.	2.1	60
44	Focal Salvage Guided by T2-Weighted and Dynamic Contrast-Enhanced Magnetic Resonance Imaging for Prostate Cancer Recurrences. International Journal of Radiation Oncology Biology Physics, 2010, 76, 741-746.	0.4	59
45	Doseâ€“surface maps identifying local doseâ€“effects for acute gastrointestinal toxicity after radiotherapy for prostate cancer. Radiotherapy and Oncology, 2015, 117, 515-520.	0.3	59
46	Tumor Trailing for Liver SBRT on the MR-Linac. International Journal of Radiation Oncology Biology Physics, 2019, 103, 468-478.	0.4	55
47	Multiatlasâ€based segmentation with preregistration atlas selection. Medical Physics, 2013, 40, 091701.	1.6	54
48	FDG-PET and diffusion-weighted MRI in head-and-neck cancer patients: Implications for dose painting. Radiotherapy and Oncology, 2013, 106, 250-254.	0.3	51
49	Influence of daily setup measurements and corrections on the estimated delivered dose during IMRT treatment of prostate cancer patients. Radiotherapy and Oncology, 2009, 90, 291-298.	0.3	49
50	Machine learning-based analysis of CT radiomics model for prediction of colorectal metachronous liver metastases. Abdominal Radiology, 2021, 46, 249-256.	1.0	47
51	Integrated MRI-guided radiotherapy â€” opportunities and challenges. Nature Reviews Clinical Oncology, 2022, 19, 458-470.	12.5	47
52	Comparison of biologically equivalent doseâ€“volume parameters for the treatment of prostate cancer with concomitant boost IMRT versus IMRT combined with brachytherapy. Radiotherapy and Oncology, 2008, 88, 46-52.	0.3	45
53	Intrafraction motion in patients with cervical cancer: The benefit of soft tissue registration using MRI. Radiotherapy and Oncology, 2009, 93, 115-121.	0.3	44
54	Magnetic resonance imaging for prostate cancer radiotherapy. Physica Medica, 2016, 32, 446-451.	0.4	43

#	Article	IF	Citations
55	Magnetic Resonance-based Response Assessment and Dose Adaptation in Human Papilloma Virus Positive Tumors of the Oropharynx treated with Radiotherapy (MR-ADAPTOR): An R-IDEAL stage 2a-2b/Bayesian phase II trial. Clinical and Translational Radiation Oncology, 2018, 13, 19-23.	0.9	41
56	Accurate prostate tumour detection with multiparametric magnetic resonance imaging: Dependence on histological properties. Acta OncolÃ³gica, 2014, 53, 88-95.	0.8	39
57	A Self-Sorting Coronal 4D-MRI Method for Daily Image Guidance of Liver Lesions on an MR-LINAC. International Journal of Radiation Oncology Biology Physics, 2018, 102, 875-884.	0.4	37
58	Patterns of Care, Tolerability, and Safety of the First Cohort of Patients Treated on a Novel High-Field MR-Linac Within the MOMENTUM Study: Initial Results From a Prospective Multi-Institutional Registry. International Journal of Radiation Oncology Biology Physics, 2021, 111, 867-875.	0.4	37
59	Quantitative Magnetic Resonance Imaging for Biological Image-Guided Adaptive Radiotherapy. Frontiers in Oncology, 2020, 10, 615643.	1.3	37
60	Contouring of prostate tumors on multiparametric MRI: Evaluation of clinical delineations in a multicenter radiotherapy trial. Radiotherapy and Oncology, 2018, 128, 321-326.	0.3	36
61	Phaseâ€based arterial input function measurements in the femoral arteries for quantification of dynamic contrastâ€enhanced (DCE) MRI and comparison with DCEâ€CT. Magnetic Resonance in Medicine, 2011, 66, 1267-1274.	1.9	34
62	An accurate calibration method of the multileaf collimator valid for conformal and intensity modulated radiation treatments. Physics in Medicine and Biology, 2004, 49, 2631-2643.	1.6	32
63	Biochemical recurrence prediction after radiotherapy for prostate cancer with T2w magnetic resonance imaging radiomic features. Physics and Imaging in Radiation Oncology, 2018, 7, 9-15.	1.2	32
64	Patterns of Failure Following External Beam Radiotherapy With or Without an Additional Focal Boost in the Randomized Controlled FLAME Trial for Localized Prostate Cancer. European Urology, 2022, 82, 252-257.	0.9	32
65	Healthâ€related quality of life 3â€ƒyears after highâ€dose intensityâ€modulated radiotherapy with gold fiducial markerâ€based position verification. BJU International, 2009, 103, 762-767.	1.3	31
66	Partial boosting of prostate tumours. Radiotherapy and Oncology, 2001, 61, 117-126.	0.3	30
67	Oropharyngeal primary tumor segmentation for radiotherapy planning on magnetic resonance imaging using deep learning. Physics and Imaging in Radiation Oncology, 2021, 19, 39-44.	1.2	30
68	Internal motion of the vagina after hysterectomy for gynaecological cancer. Radiotherapy and Oncology, 2011, 98, 244-248.	0.3	29
69	Dynamic Contrast-enhanced CT for Prostate Cancer: Relationship between Image Noise, Voxel Size, and Repeatability. Radiology, 2010, 256, 976-984.	3.6	27
70	Influence of Antiflatulent Dietary Advice on Intrafraction Motion for Prostate Cancer Radiotherapy. International Journal of Radiation Oncology Biology Physics, 2011, 81, e401-e406.	0.4	26
71	Free-form image registration regularized by a statistical shape model: application to organ segmentation in cervical MR. Computer Vision and Image Understanding, 2013, 117, 1119-1127.	3.0	26
72	A tumour control probability model for radiotherapy of prostate cancer using magnetic resonance imaging-based apparent diffusion coefficient maps. Radiotherapy and Oncology, 2016, 119, 111-116.	0.3	26

#	Article	IF	Citations
73	Retrospective self-sorted 4D-MRI for the liver. Radiotherapy and Oncology, 2018, 127, 474-480.	0.3	25
74	Position shifts and volume changes of pelvic and para-aortic nodes during IMRT for patients with cervical cancer. Radiotherapy and Oncology, 2014, 111, 442-445.	0.3	24
75	Performance of a fast and highâ€resolution multiâ€echo spinâ€echo sequence for prostate T₂ mapping across multiple systems. Magnetic Resonance in Medicine, 2018, 79, 1586-1594.	1.9	24
76	Stereotactic body radiation therapy with optional focal lesion ablative microboost in prostate cancer: Topical review and multicenter consensus. Radiotherapy and Oncology, 2019, 140, 131-142.	0.3	24
77	Histopathological Features of MRIâ€Invisible Regions of Prostate Cancer Lesions. Journal of Magnetic Resonance Imaging, 2020, 51, 1235-1246.	1.9	24
78	A 1.5 T transverse magnetic field in radiotherapy of rectal cancer: Impact on the dose distribution. Medical Physics, 2015, 42, 7182-7189.	1.6	23
79	Prostate fiducial marker detection with the use of multi-parametric magnetic resonance imaging. Physics and Imaging in Radiation Oncology, 2017, 1, 14-20.	1.2	23
80	Multicenter validation of prostate tumor localization using multiparametric <scp>MRI</scp> and prior knowledge. Medical Physics, 2017, 44, 949-961.	1.6	23
81	Optimal 68Ga-PSMA and 18F-PSMA PET window levelling for gross tumour volume delineation in primary prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 1211-1218.	3.3	23
82	A Double-Blind Placebo-Controlled Randomized Clinical Trial With Magnesium Oxide to Reduce Intrafraction Prostate Motion for Prostate Cancer Radiotherapy. International Journal of Radiation Oncology Biology Physics, 2012, 83, 653-660.	0.4	22
83	Why prostate tumour delineation based on apparent diffusion coefficient is challenging: An exploration of the tissue microanatomy. Acta OncolÃ³gica, 2013, 52, 1629-1636.	0.8	22
84	Quantitative 3T multiparametric MRI of benign and malignant prostatic tissue in patients with and without local recurrent prostate cancer after externalâ€beam radiation therapy. Journal of Magnetic Resonance Imaging, 2019, 50, 269-278.	1.9	22
85	Daily Intravoxel Incoherent Motion (IVIM) In Prostate Cancer Patients During MR-Guided Radiotherapyâ€"A Multicenter Study. Frontiers in Oncology, 2021, 11, 705964.	1.3	22
86	Repeatability of dose painting by numbers treatment planning in prostate cancer radiotherapy based on multiparametric magnetic resonance imaging. Physics in Medicine and Biology, 2017, 62, 5575-5588.	1.6	21
87	Integration of quantitative imaging biomarkers in clinical trials for MR-guided radiotherapy: Conceptual guidance for multicentre studies from the MR-Linac Consortium Imaging Biomarker Working Group. European Journal of Cancer, 2021, 153, 64-71.	1.3	21
88	Feasibility and measurement precision of 3D quantitative blood flow mapping of the prostate using dynamic contrast-enhanced multi-slice CT. Physics in Medicine and Biology, 2006, 51, 4329-4343.	1.6	20
89	Urethral and bladder doseâ€"effect relations for late genitourinary toxicity following external beam radiotherapy for prostate cancer in the FLAME trial. Radiotherapy and Oncology, 2022, 167, 127-132.	0.3	20
90	The use of probability maps to deal with the uncertainties in prostate cancer delineation. Radiotherapy and Oncology, 2010, 94, 168-172.	0.3	19

#	Article	IF	Citations
91	Tracer Kinetic Model Selection for Dynamic Contrast-Enhanced Computed Tomography Imaging of Prostate Cancer. Investigative Radiology, 2012, 47, 41-48.	3.5	19
92	Introduction: Systems for Magnetic Resonance Image Guided Radiation Therapy. Seminars in Radiation Oncology, 2014, 24, 192.	1.0	19
93	³¹P MR spectroscopic imaging combined with ¹H MR spectroscopic imaging in the human prostate using a double tuned endorectal coil at 7T. Magnetic Resonance in Medicine, 2014, 72, 1516-1521.	1.9	19
94	An MRI-based mid-ventilation approach for radiotherapy of the liver. Radiotherapy and Oncology, 2016, 121, 276-280.	0.3	18
95	CT-Based Radiomics Analysis Before Thermal Ablation to Predict Local Tumor Progression for Colorectal Liver Metastases. CardioVascular and Interventional Radiology, 2021, 44, 913-920.	0.9	18
96	Difficulties and potential of correlating local recurrences in prostate cancer with the delivered local dose. Radiotherapy and Oncology, 2009, 93, 180-184.	0.3	17
97	The effect of hormonal treatment on conspicuity of prostate cancer: Implications for focal boosting radiotherapy. Radiotherapy and Oncology, 2012, 103, 233-238.	0.3	17
98	Introduction: Magnetic Resonance Imaging Comes of Age in Radiation Oncology. Seminars in Radiation Oncology, 2014, 24, 149-150.	1.0	17
99	Imaging predictors of treatment outcomes in rectal cancer: An overview. Critical Reviews in Oncology/Hematology, 2018, 129, 153-162.	2.0	17
100	Correcting geometric image distortions in sliceâ€based 4Dâ€MRI on the MRâ€linac. Medical Physics, 2019, 46, 3044-3054.	1.6	17
101	MRI basics for radiation oncologists. Clinical and Translational Radiation Oncology, 2019, 18, 74-79.	0.9	17
102	Significant tumor shift in patients treated with stereotactic radiosurgery for brain metastasis. Clinical and Translational Radiation Oncology, 2017, 2, 23-28.	0.9	16
103	Quantitative MRI Changes During Weekly Ultra-Hypofractionated Prostate Cancer Radiotherapy With Integrated Boost. Frontiers in Oncology, 2019, 9, 1264.	1.3	16
104	Gross tumor volume and clinical target volume in prostate cancer: How do satellites relate to the index lesion. Radiotherapy and Oncology, 2015, 115, 96-100.	0.3	15
105	Role of Prostate MR Imaging in Radiation Oncology. Radiologic Clinics of North America, 2018, 56, 319-325.	0.9	15
106	MRI visibility of gold fiducial markers for image-guided radiotherapy of rectal cancer. Radiotherapy and Oncology, 2019, 132, 93-99.	0.3	15
107	Predicting and implications of target volume changes of brain metastases during fractionated stereotactic radiosurgery. Radiotherapy and Oncology, 2020, 142, 175-179.	0.3	15
108	Phantom-based quality assurance for multicenter quantitative MRI in locally advanced cervical cancer. Radiotherapy and Oncology, 2020, 153, 114-121.	0.3	15

#	Article	IF	Citations
109	Knowledge-Based Assessment of Focal Dose Escalation Treatment Plans in Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2020, 108, 1055-1062.	0.4	14
110	Establishing implantation uncertainties for focal brachytherapy with I-125 seeds for the treatment of localized prostate cancer. Acta OncolÃ³gica, 2015, 54, 839-846.	0.8	13
111	Quantitative Imaging for Radiation Oncology. International Journal of Radiation Oncology Biology Physics, 2018, 102, 683-686.	0.4	13
112	68Ga-PSMA-11 PET, 18F-PSMA-1007 PET, and MRI for Gross Tumor Volume Delineation in Primary Prostate Cancer: Intermodality and Intertracer Variability. Practical Radiation Oncology, 2021, 11, 202-211.	1.1	13
113	Impact of tumour invasion on seminal vesicles mobility in radiotherapy of prostate cancer. Radiotherapy and Oncology, 2015, 117, 283-287.	0.3	12
114	Histopathology-derived modeling of prostate cancer tumor control probability: Implications for the dose to the tumor and the gland. Radiotherapy and Oncology, 2016, 119, 97-103.	0.3	12
115	Twoâ€dimensional EPID dosimetry for an MRâ€linac: Proof of concept. Medical Physics, 2019, 46, 4193-4203.	1.6	12
116	Geometrical and dosimetric evaluation of breast target volume auto-contouring. Physics and Imaging in Radiation Oncology, 2019, 12, 38-43.	1.2	12
117	Validation of a 4D-MRI guided liver stereotactic body radiation therapy strategy for implementation on the MR-linac. Physics in Medicine and Biology, 2021, 66, 105010.	1.6	12
118	Polarized Fluorescence Depletion Reports Orientation Distribution and Rotational Dynamics of Muscle Cross-Bridges. Biophysical Journal, 2002, 83, 1050-1073.	0.2	11
119	Functional MRI for tumor delineation in prostate radiation therapy. Imaging in Medicine, 2011, 3, 219-231.	0.0	11
120	Re-distribution of brachytherapy dose using a differential dose prescription adapted to risk of local failure in low-risk prostate cancer patients. Radiotherapy and Oncology, 2015, 115, 308-313.	0.3	11
121	Diffusion-weighted-preparation (D-prep) MRI as a future extension of SPECT/CT based surgical planning for sentinel node procedures in the head and neck area?. Oral Oncology, 2016, 60, 48-54.	0.8	11
122	A Deep Learning-based correction to EPID dosimetry for attenuation and scatter in the Unity MR-Linac system. Physica Medica, 2020, 71, 124-131.	0.4	11
123	Expression of hypoxia-inducible factor-1Î± and -2Î± in whole-mount prostate histology: Relation with dynamic contrast-enhanced MRI and Gleason score. Oncology Reports, 2013, 29, 2249-2254.	1.2	10
124	Planning feasibility of extremely hypofractionated prostate radiotherapy on a 1.5â€T magnetic resonance imaging guided linear accelerator. Physics and Imaging in Radiation Oncology, 2019, 11, 16-20.	1.2	10
125	Improved repeatability of dynamic contrastâ€enhanced MRI using the complex MRI signal to derive arterial input functions: a testâ€retest study in prostate cancer patients. Magnetic Resonance in Medicine, 2019, 81, 3358-3369.	1.9	10
126	Quantitative 3-T multi-parametric MRI and step-section pathology of recurrent prostate cancer patients after radiation therapy. European Radiology, 2019, 29, 4160-4168.	2.3	10

#	Article	IF	Citations
127	Longitudinal Correlations Between Intravoxel Incoherent Motion (IVIM) and Dynamic Contrast-Enhanced (DCE) MRI During Radiotherapy in Prostate Cancer Patients. Frontiers in Oncology, 0, 12, .	1.3	9
128	Towards intrinsic R2* imaging in the prostate at 3 and 7 tesla. Magnetic Resonance Imaging, 2017, 42, 16-21.	1.0	8
129	Multimodal imaging for radiation therapy planning in patients with primary prostate cancer. Physics and Imaging in Radiation Oncology, 2018, 8, 8-16.	1.2	8
130	Clinical workflow for treating patients with a metallic hip prosthesis using magnetic resonance imaging-guided radiotherapy. Physics and Imaging in Radiation Oncology, 2020, 15, 85-90.	1.2	8
131	3D dosimetric verification of unity MR-linac treatments by portal dosimetry. Radiotherapy and Oncology, 2020, 146, 161-166.	0.3	8
132	Joint Registration and Segmentation via Multi-Task Learning for Adaptive Radiotherapy of Prostate Cancer. IEEE Access, 2021, 9, 95551-95568.	2.6	8
133	Radiation oncology in the new virtual and digital era. Radiotherapy and Oncology, 2021, 154, A1-A4.	0.3	8
134	Anorectal doseâ€“effect relations for late gastrointestinal toxicity following external beam radiotherapy for prostate cancer in the FLAME trial. Radiotherapy and Oncology, 2021, 162, 98-104.	0.3	8
135	Multiparametric MRI Tumor Probability Model for the Detection of Locally Recurrent Prostate Cancer After Radiation Therapy: Pathologic Validation and Comparison With Manual Tumor Delineations. International Journal of Radiation Oncology Biology Physics, 2019, 105, 140-148.	0.4	7
136	PROTECT: Prospective Phase-II-Trial Evaluating Adaptive Proton Therapy for Cervical Cancer to Reduce the Impact on Morbidity and the Immune System. Cancers, 2021, 13, 5179.	1.7	7
137	Personalised radiation therapy taking both the tumour and patient into consideration. Radiotherapy and Oncology, 2022, 166, A1-A5.	0.3	7
138	Eye-specific quantitative dynamic contrast-enhanced MRI analysis for patients with intraocular masses. Magnetic Resonance Materials in Physics, Biology, and Medicine, 2022, 35, 311-323.	1.1	7
139	Reproducibility of the MRI-defined spinal cord position in stereotactic radiotherapy for spinal oligometastases. Radiotherapy and Oncology, 2014, 113, 230-234.	0.3	6
140	Monitoring early changes in rectal tumor morphology and volume during 5â€¯weeks of preoperative chemoradiotherapy â€“ An evaluation with sequential MRIs. Radiotherapy and Oncology, 2018, 126, 431-436.	0.3	6
141	A multiâ€institutional analysis of a general pelvis continuous Hounsfield unit synthetic CT software for radiotherapy. Journal of Applied Clinical Medical Physics, 2021, 22, 207-215.	0.8	5
142	Reply to I. R. Vogelius et al. Journal of Clinical Oncology, 2021, 39, 3086-3087.	0.8	5
143	In Reply to Dr. Xiao et al.. International Journal of Radiation Oncology Biology Physics, 2009, 75, 318.	0.4	4
144	Impact of contrast agent injection duration on dynamic contrastâ€enhanced MRI quantification in prostate cancer. NMR in Biomedicine, 2018, 31, e3946.	1.6	4

#	Article	IF	Citations
145	Applicator visualization using ultrashort echo time MRI for high-dose-rate endorectal brachytherapy. Brachytherapy, 2020, 19, 618-623.	0.2	4
146	The impact of image acquisition time on registration, delineation and image quality for magnetic resonance guided radiotherapy of prostate cancer patients. Physics and Imaging in Radiation Oncology, 2021, 19, 85-89.	1.2	4
147	How quality influences the clinical outcome of external beam radiotherapy for localized prostate cancer. BJU International, 2008, 101, 944-947.	1.3	3
148	Benefit of adaptive CT-based treatment planning in high-dose-rate endorectal brachytherapy for rectal cancer. Brachytherapy, 2018, 17, 78-85.	0.2	3
149	Imaging for radiation treatment planning and monitoring in prostate Cancer: Precision, personalization, individualization of therapy. Physics and Imaging in Radiation Oncology, 2019, 11, 61-62.	1.2	3
150	Radiotherapy quality assurance for mesorectum treatment planning within the multi-center phase II STAR-TReC trial: Dutch results. Radiation Oncology, 2020, 15, 41.	1.2	3
151	Pseudo-CT image generation from mDixon MRI images using fully convolutional neural networks. , 2019, , .		3
152	Probabilistic target definition and planning in patients with prostate cancer. Physics in Medicine and Biology, 2021, 66, 215011.	1.6	3
153	T1Ï•for Radiotherapy Treatment Response Monitoring in Rectal Cancer Patients: A Pilot Study. Journal of Clinical Medicine, 2022, 11, 1998.	1.0	3
154	The Effects of Enzalutamide Monotherapy on Multiparametric 3T MR Imaging in Prostate Cancer. Urology Case Reports, 2016, 7, 67-69.	0.1	2
155	Feasibility of Gold Fiducial Markers as a Surrogate for Gross Tumor Volume Position in Image-Guided Radiation Therapy of Rectal Cancer. International Journal of Radiation Oncology Biology Physics, 2019, 105, 1151-1159.	0.4	2
156	Locally advanced rectal cancer: 3D diffusion-prepared stimulated-echo turbo spin-echo versus 2D diffusion-weighted echo-planar imaging. European Radiology Experimental, 2020, 4, 9.	1.7	2
157	Segmentation of Cervical Images by Inter-subject Registration with a Statistical Organ Model. Lecture Notes in Computer Science, 2012, , 240-247.	1.0	1
158	Master protocol trial design for technical feasibility of MR-guided radiotherapy. Radiotherapy and Oncology, 2022, 166, 33-36.	0.3	1
159	Accuracy of PET/MRI coregistration of cervical lesions. Nuclear Medicine Communications, 2016, 37, 997-998.	0.5	0
160	Tribute to David Thwaites. Radiotherapy and Oncology, 2020, 153, 5-6.	0.3	0
161	Characterization of Gas Electron Multiplierâ€based detector for external beam radiation therapy dosimetry. Medical Physics, 2021, 48, 1931-1940.	1.6	0
162	The impact of anatomical changes during photon or proton based radiation treatment on tumor dose in glioblastoma dose escalation trials. Radiotherapy and Oncology, 2021, 164, 202-208.	0.3	0

#	Article	IF	Citations
163	Reply to Kamal Kant Sahuâ€™s Letter to the Editor re: Veerle H. Groen, Karin Haustermans, Floris J. Pos, et al. Patterns of Failure Following External Beam Radiotherapy With or Without an Additional Focal Boost in the Randomized Controlled FLAME Trial for Localized Prostate Cancer. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2021.12.012. European Urology, 2022, , .	0.9	0
164	â€œWho needs a mean dose if you can FLAME?â€• Radiotherapy and Oncology, 2022, , .	0.3	0